Early chronic kidney disease-mineral bone disorder stimulates vascular calcification

Kidney International

Volumn 85, Issue 1, 2014, Pages 142-150

  Fang, Yifu ^a   Ginsberg, Charles ^a   Sugatani, Toshifumi ^a   Monier Faugere, Marie Claude ^b   Malluche, Hartmut ^b   Hruska, Keith A ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

a klotho; CKD MBD; FGF23; vascular calcification

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; KLOTHO PROTEIN; PARATHYROID HORMONE; SCLEROSTIN; TRANSCRIPTION FACTOR RUNX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER SYNDROME; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION; KIDNEY FAILURE; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL OSTEODYSTROPHY;

ANIMALS; BONE DISEASES, METABOLIC; BONE REMODELING; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; MALE; MICE; MICE, INBRED C57BL; PROTEINS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION;

EID: 84891559651     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.271     Document Type: Article

References (49)

1. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953. (Pubitemid 43924257)
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med 2004; 351: 1296-1305.
3. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
4. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528. (Pubitemid 41725150)
5. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663. (Pubitemid 38392981)
6. Moe SM, Radcliffe JS, White KE et al. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res 2011; 26: 2672-2681.
7. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942. (Pubitemid 34258697)
8. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal diseases: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740. (Pubitemid 37098542)
9. Hruska K, Mathew S, Lund R et al. Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Kidney Int 2011; 79(Suppl 121): S9-S13.
10. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New Engl J Med 2008; 359: 584-592.
11. Arnlov J, Carlsson AC, Sundstrom J et al. Higher fibroblast growth factor- 23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013; 83: 160-166.
12. Rennenberg RJMW Kessels AGH, Schurgers LJ et al. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag 2009; 5: 185-197.
13. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-567. (Pubitemid 39274370)
14. Mathew S, Lund R, Strebeck F et al. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007; 18: 122-130. (Pubitemid 46053427)
15. El-Abbadi MM, Pai AS, Leaf EM et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009; 75: 1297-1307.
16. Chen NX, O'Neill KD, Duan D et al. Phosphorus and uremic serum upregulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002; 62: 1724-1731. (Pubitemid 35286280)
17. Shanahan CM, Crouthamel MH, Kapustin A et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711.
18. Hill KM, Martin BR, Wastney ME et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2012; 83: 959-966.
19. Pereira RC, Juppner H, Azucena-Serrano CE et al. Patterns of FGF-23, DMP1 and MEPE expression in patients with chronic kidney disease. Bone 2009; 45: 1161-1168.
20. Fang Y, Zhang Y, Mathew S et al. Early chronic kidney disease (CKD) stimulates vascular calcification (VC) and decreased bone formation rates prior to positive phosphate balance. J Am Soc Nephrol 2009; 20: 36A.
21. Sabbagh Y, Graciolli FG, O'Brien S et al. Repression of osteocyte Wnt/bcatenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012; 27: 1757-1772.
22. Oliveira RB, Cancela ALE, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291.
23. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
24. Babij P, Zhao W, Small C et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003; 18: 960-974. (Pubitemid 37294932)
25. Little RD, Carulli JP, DelMastro RG et al. A mutation in the LDL receptorrelated protein 5 gene results in the autosomal dominant high-bonemass trait. Am J Hum Genet 2002; 70: 11-19. (Pubitemid 34031693)
26. Lund RJ, Davies MR, Brown AJ et al. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 2004; 15: 359-369. (Pubitemid 38140776)
27. Mahmoodi BK, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380: 1649-1661.
28. Fox CS, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380: 1662-1673.
29. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 2003; 14: 1559-1567. (Pubitemid 36687057)
30. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-136.
31. Voigt M, Fischer D-C, Rimpau M et al. Fibroblast growth factor (FGF)-23 and fetuin-A in calcified carotid atheroma. Histopathology 2010; 56: 775-788.
32. Lim K, Lu T-S, Molostvov G et al. Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012; 125: 2243-2255.
33. Davies MR, Lund RJ, Mathew S et al. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005; 16: 917-928. (Pubitemid 41710302)
34. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008. (Pubitemid 350224109)
35. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003; 14: S305-S309. (Pubitemid 37052395)
36. Mathew S, Tustison KS, Sugatani T et al. The mechanism of phosphorus as a cardiovascular risk factor in chronic kidney disease. J Am Soc Nephrol 2008; 19: 1092-1105.
37. Speer MY, Yang HY, Brabb T et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104: 733-741.
38. Shanahan CM, Cary NRB, Salisbury JR et al. Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 1999; 100: 2168-2176.
39. Smith RC, O'Bryan LM, Farrow EG et al. Circulating aKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest 2012; 122: 4710-4715.
40. Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882.
41. Shanahan CM, Proudfoot D, Tyson KL et al. Expression of mineralisationregulating proteins in association with human vascular calcification Z Kardiol 2000; 89: S063-S068.
42. Moe SM, O'Neill KD, Duan D et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002; 61: 638-647. (Pubitemid 34102607)
43. Donate-Correa J, Mora-Ferna'ndez C, Marti'nez-Sanz R et al. Expression of FGF23/KLOTHO system in human vascular tissue. Int J Cardiol 2011; 165: 179-183.
44. Zhu D, Mackenzie NCW, Milla'n JL et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011; 6: e19595.
45. Scialla JJ, Lau WL, Reilly MP et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013; 83: 1159-1168.
46. Slatopolsky E, Caglar S, Pennell JP. On the pathogenesis of hyperparathyroidism in chronic experimental insufficiency in the dog. J Clin Invest 1971; 50: 492-499.
47. Stubbs JR, He N, Idiculla A et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 2012; 27: 38-46.
48. Lecka-Czernik B, Gubrij I, Moerman EJ et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999; 74: 347-371.
49. Seiler S, Wen M, Roth HJ et al. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 2013; 83: 121-128.